A secondary analysis of the randomized controlled MOVe-OUT trial found additional clinical benefits of molnupiravir for nonhospitalized participants with mild to moderate COVID-19 and risk factors for progression to severe disease. Participants treated with molnupiravir had a decreased need for respiratory interventions and fewer COVID-19-related acute care visits compared to those in the placebo group through day 29. The findings are published in Annals of Internal Medicine.